Patents Assigned to UNIVERSITÉ PARIS DESCARTES
-
Publication number: 20200383973Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.Type: ApplicationFiled: July 21, 2020Publication date: December 10, 2020Applicants: Universite Paris Descartes, Assistance Publique - Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Sorbonne UniversiteInventors: Nicolas Dupin, Vincent Calvez, Philippe Grange, Anne-Geneviève Marcelin
-
Patent number: 10842776Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to gammaherpesvirinae, in particular to the human herpesvirus 8 (HHV8) or the human herpes virus 4 (HHV4), and pharmaceutical compositions containing such compounds.Type: GrantFiled: June 28, 2017Date of Patent: November 24, 2020Assignees: Assistance Publique—Hopitaua de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM), Sorbonne Unicersite, Universite Paris Descartes, Centre National de la Recherche Scientifique (CNRS)Inventors: Nicolas Dupin, Anne-Geneviève Marcelin, Vincent Calvez, Philippe Grange
-
Publication number: 20200353072Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.Type: ApplicationFiled: July 23, 2020Publication date: November 12, 2020Applicants: DBV Technologies, Assistance Publique Hopitaux De Paris, Universite Paris DescartesInventors: Christophe DUPONT, Pierre-Henri BENHAMOU, Bertrand DUPONT
-
Publication number: 20200347121Abstract: The present invention provides a medicament comprising as active ingredient an inhibitor of Coll2-1 peptide activity and/or an inhibitor of Coll2-1NO2 peptide activity for use in the prevention and/or treatment of osteoarthritis. Further, the present invention provides a medicament comprising as active ingredient an inhibitor of Coll2-1 peptide activity and/or an inhibitor of Coll2-1NO2 peptide activity for use in the prevention and/or treatment of rheumatic and musculoskeletal diseases (RMDs).Type: ApplicationFiled: May 4, 2020Publication date: November 5, 2020Applicants: Université de Liège, Université Paris Descartes, Assistance Publique Hopitaux de Paris, Institut National de la Santé et de la Recherche MédicaleInventors: Yves HENROTIN, Cécile LAMBERT, Didier BORDERIE, François RANNOU
-
Patent number: 10793909Abstract: The present invention relates to methods for predicting the survival time of patients with decompensated alcoholic cirrhosis. In particular, the present invention relates to a method for predicting the survival time of a patient with decompensated alcoholic cirrhosis comprising i) determining the expression level of OAS2 or MX2 in a sample of peripheral blood mononuclear cells obtained from the patient, ii) comparing the level determined at step i) with a predetermined reference value and iii) and concluding that the patient will have a short survival time when the level determined at step i) is higher than its predetermined reference value or concluding that the patient will have a long survival time when the level determined at step i) is lower than the predetermined reference value.Type: GrantFiled: November 9, 2016Date of Patent: October 6, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), UNIVERSITE PARIS DIDEROT—PARIS 7Inventors: Richard Moreau, Emmanuel Weiss, Pierre-Emmanuel Rautou
-
Patent number: 10787506Abstract: The present invention relates to a neutralising antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralises the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralising antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2, a H-CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having at least 90% of identity with SEQ ID NO:6, a L-CDR2 having at least 90% of identity with SEQ ID NO:7 and a L-CDR3 region having at least 90% of identity with SEQ ID NO:8. The present invention also provides the use of such antibodies in the treatment of cancer.Type: GrantFiled: November 15, 2018Date of Patent: September 29, 2020Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris DescartesInventor: Patricia Forgez
-
Patent number: 10766873Abstract: The present invention relates to compounds of the following general formula (I) or (II): or a pharmaceutically acceptable salt and/or solvate thereof, for use in the treatment and/or in the prevention of ErbB2 dependent cancers, and pharmaceutical compositions containing such compounds.Type: GrantFiled: January 11, 2017Date of Patent: September 8, 2020Assignees: Centre National de la Recherche Scientifique (CNRS), Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris DescartesInventors: Sandrine Bourdoulous, Camille Faure
-
Patent number: 10758610Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.Type: GrantFiled: April 25, 2019Date of Patent: September 1, 2020Assignees: DBV Technologies, Assistance Publique Hopitaux De Paris, Universite Paris DescartesInventors: Christophe Dupont, Pierre-Henri Benhamou, Bertrand Dupont
-
Publication number: 20200264166Abstract: A process for isolating or extracting rare cells from a biological sample comprising filtering a biological sample, which may be treated or diluted, through a filter that has a pore size, pore density or other physical properties that retain rare cells, but which permits other kinds of cells to pass through the filter. This process also comprises multiple analyses performed on rare cells after their extraction or isolation by filtration to diagnostically identify the presence of rare cells in a biological sample and to use their diagnostic identification and molecular characterization for diagnostic purposes such as for early diagnosis of diseases, namely for early diagnosis of cancer and to select, guide, monitor treatments and in particular to select targeted treatments and to monitor the response and/or resistance to them.Type: ApplicationFiled: January 17, 2020Publication date: August 20, 2020Applicants: RARECELLS SAS, UNIVERSITE DE NICE SOPHIA ANTIPOLIS, CENTRE HOSPITALIER UNIVERSITAIRE DE NICE, UNIVERSITE PARIS DESCARTES, Assistance Publique-Hopitaux de Paris (AP-HP), Institut National de la Sante et de la Recherche Medicale (Inserm)Inventors: Patrizia PATERLINI-BRECHOT, Paul HOFMAN, Sophie Marie Genevieve LAGET, Thierry CAPIOD
-
Publication number: 20200248269Abstract: The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient.Type: ApplicationFiled: December 2, 2019Publication date: August 6, 2020Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARISInventors: Jerome Galon, Franck Pages, Bernhard MLECNIK, Herve FRIDMAN
-
Patent number: 10731197Abstract: The present invention relates to a method for detecting or quantifying CTP in a cell sample comprising at least two nucleotide triphosphates by cationic ion pairing chromatography coupled to mass spectrometry, to a method for detecting or quantifying CTP synthase activity based on the method for detecting or quantifying CTP, and to their use in methods for screening potential immunosuppressive or anti-cancer compounds and in methods for determining the appropriate dose of an immunosuppressive or anti-cancer compound inhibiting CTP synthase activity for a treated subject.Type: GrantFiled: October 10, 2016Date of Patent: August 4, 2020Assignees: Assitance Publique-Hopitaux de Paris, Imagine Institut Des Maladies Genetiques Necker Enfants Malades, Universite Paris Descartes, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)Inventors: Sylvia Sanquer, Anne-Claire Boschat, Sylvain Latour, Emmanuel Martin, Robert Barouki
-
Publication number: 20200222418Abstract: The present invention provides a phenothiazine derivative of formula (I) for use in preventing and/or treating infection caused by bacteria carrying Type IV pili, such as N. meningitidis, and more specifically for use in preventing and/or treating meningitis. The present invention further relates to a composition for the use in preventing and/or treating infection caused by bacteria carrying Type IV pili, such as purpura fulminans and meningitis, comprising a phenothiazine derivative of formula (I) and an antibiotic selected from the group consisting of beta-lactams and aminoglycosides, and/or dexamethasone.Type: ApplicationFiled: July 6, 2018Publication date: July 16, 2020Applicants: Centre National de la Recherche Scientifique (CNRS), Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris DescartesInventors: Sandrine Bourdoulous, Kévin Denis, Loïc Le Guennec
-
Patent number: 10671936Abstract: The invention relates to a method for clustering nodes of a network, the network comprising nodes associated with message edges of text data, the method comprising an initialization step of determination of a first initial clustering of the nodes, and a step of iterative inference of a generative model of text documents. Edges are modeled with a Stochastic Block Model (SBM) and the sets of documents between and within clusters are modeled according to a generative model of documents. The inference step comprises iteratively modelling the text documents and the underlying topics of their textual content, and updating the clustering as a function of the modelling, until a convergence criterion is fulfilled and an optimized clustering and corresponding optimized values of the parameters of the models are output.Type: GrantFiled: April 6, 2017Date of Patent: June 2, 2020Assignees: Universite Paris Descartes, Universite Paris | Pantheon-Sorbonne, Centre National de la Recherche Scientifique (CNRS)Inventors: Charles Bouveyron, Pierre Latouche
-
Patent number: 10662482Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.Type: GrantFiled: June 8, 2016Date of Patent: May 26, 2020Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CENTRE HENRI BECQUEREL, UNIVERSITE PARIS DESCARTES, UNIVERSITY PIERRE ET MARIE CURIE (PARIS 6), UNIVERSITE PARIS-SUDInventors: Franck Viguie, Olivier Bernard, Michaela Fontenay, Christian Bastard, Francois Delhommeau, William Vainchenker
-
Publication number: 20200155725Abstract: A regenerative material in the connective tissues (such as bone, dentin or pulp) regeneration field. More precisely, a connective tissue regenerative material, preferably a bone, dentin or pulp regenerative material, including: a porous polymer matrix having interconnected pores; and non-hydrated calcium silicate particles; wherein: the polymer matrix is anhydrous; the non-hydrated calcium silicate particles have a d50 granulometry, preferably ranging from 0.05 ?m to less than the average diameter size of the pores of the matrix; and the non-hydrated calcium silicate particles being coated on the inside walls of the pores of the matrix. Also, a method for preparing the connective tissue regenerative material and uses of the regenerative materials, such as in the dental field; especially, for providing regenerative materials with improved biomechanical and osteoinductive properties (i.e.Type: ApplicationFiled: April 13, 2018Publication date: May 21, 2020Applicants: SEPTODONT OU SEPTODONT SAS OU SPECIALITES SEPTODONT, UNIVERSITÉ PARIS DESCARTES - PARIS V, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), SORBONNE UNIVERSITE, UNIVERSITE PARIS DIDEROT (PARIS 7)Inventors: Fleur BERES, Gilles RICHARD, Arnaud DESSOMBZ, Stéphane SIMON, Juliane ISAAC
-
Patent number: 10653687Abstract: The present invention relates to methods and pharmaceutical compositions for treating rhabdomyolysis.Type: GrantFiled: November 16, 2016Date of Patent: May 19, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, FONDATION IMAGINE, UNIVERSITÉ PARIS DESCARTES ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Pascale De Lonlay-Debeney, Corinne Lebreton, Yamina Hamel, Francois-Xavier Mauvais, Peter Van Endert
-
Patent number: 10647752Abstract: The present invention relates to agents capable of inhibiting the binding between Leptin and Neuropilin-1 (NRP1) and uses thereof in the therapeutic field.Type: GrantFiled: September 21, 2016Date of Patent: May 12, 2020Assignees: INSERM (Institut National de la Santé et de la Recherche Medicale), Fondation Imagine, Assistance Publique-Hopitaux de Paris (APHP), Université Paris Descartes, Centre National de la Recherche Scientifique (CNRS), Université de Bourgogne, CNAM—Conservatoire National des Arts at MetierInventors: Zakia Belaid-Choucair, Olivier Hermine, Matthieu Montes, Carmen Garrido-Fleury, Renaud Seigneuric, Guillaume Marcion
-
Patent number: 10624838Abstract: The present invention relates to the use of gingival fibroblast-derived products to reduce hair loss and promote hair growth. Specifically, the invention relates to a product derived from gingival fibroblasts to be used in the treatment or prevention of alopecia, as well as in the promotion of natural hair growth and/or in the control of natural hair loss.Type: GrantFiled: July 9, 2014Date of Patent: April 21, 2020Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT DE RADIOPROTECTION ET DE SURETE NUCLEAIRE, ETAT FRANCAIS—MINISTERE DE AL DEFENSE—DIRECTION CENTRALE DU SERVICE DE SANTE DES ARMEES, UNIVERSITE PARIS DESCARTESInventors: Antoine Lafont, Bernard Coulomb, Jean-Jacques Lataillade, Christine Linard
-
Patent number: 10617658Abstract: The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.Type: GrantFiled: August 8, 2016Date of Patent: April 14, 2020Assignees: CENTRE HOSPITALIER NATIONAL D'OPHTALMOLOGIE QUINZE-VINGTS, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICAL (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS DESCARTESInventors: Yves Colin, Jean-Francois Girmens, Olivier Hermine, Emmanuel Heron, Michel Paques
-
Patent number: D899694Type: GrantFiled: February 8, 2018Date of Patent: October 20, 2020Assignee: UNIVERSITE PARIS DESCARTESInventors: Marianne Barbu-Roth, Vincent Forma, Joëlle Provasi, Caroline Teulier